What I Learned This Week

China and the U.S. are locked in an "arms race" to dominate genomics, gene editing, stem cells and personalized medicine—with huge implications and new potential winners.

Historically, the U.S. has been the worldwide champion of genomics and personalized medicine—conducting most of the research on the human genome. However, China is moving to leapfrog America across the precision medicine landscape, investing $9.2 billion in a 15-year project to leverage the convergence of AI with genomics. In contrast, the Obama administration allocated only $215 million for a similar initiative.China’s precision medicine program is already showing results. China’s BGI—the world’s largest DNA sequencer—has developed a technology that can map the human genome for $600—taking the lead from Illumina. BGI is also launching outsourcing sequencing services for a quantitative “…

Want to read more?

Subscribe Today

Already a subscriber? Login here.